M. Kraus & Co Sells 734 Shares of Johnson & Johnson $JNJ

M. Kraus & Co lessened its stake in Johnson & Johnson (NYSE:JNJ) by 1.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 50,637 shares of the company’s stock after selling 734 shares during the period. Johnson & Johnson comprises 2.3% of M. Kraus & Co’s portfolio, making the stock its 19th biggest holding. M. Kraus & Co’s holdings in Johnson & Johnson were worth $7,735,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in JNJ. GFG Capital LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $35,000. Highline Wealth Partners LLC lifted its stake in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC bought a new position in Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the first quarter valued at approximately $48,000. Finally, von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $49,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $190.66 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $192.10. The firm has a 50 day moving average of $178.48 and a 200-day moving average of $163.77. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $459.16 billion, a P/E ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $24.02 billion during the quarter. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Analyst Upgrades and Downgrades

Several brokerages recently commented on JNJ. Weiss Ratings raised Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. UBS Group set a $198.00 target price on shares of Johnson & Johnson in a report on Friday, October 3rd. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $209.00 price objective on shares of Johnson & Johnson in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $192.94.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.